aspirin has been researched along with Agnogenic Myeloid Metaplasia in 29 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0." | 5.11 | Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005) |
| " An algorithm for the treatment of patients with erythremia is proposed along with recommendations on the use of aspirin, hydroxyurea, alpha-interpheron, and imatinib." | 4.88 | [True polycythemia: current views of pathogenesis, diagnostics and treatment]. ( Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT, 2012) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "The pregnancy was uneventful." | 2.55 | Primary myelofibrosis and pregnancy outcomes after low molecular-weight heparin administration: A case report and literature review. ( Bohîlţea, RE; Cîrstoiu, MM; Dimitriu, M; Ionescu, CA; Niculescu-Mizil, E; Turcan, N; Vlădăreanu, AM; Voican, I, 2017) |
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis." | 2.52 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation." | 1.46 | Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017) |
| "Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm that occurs most commonly in the decade six of life and it is very rare in the young persons." | 1.42 | Management of myelofibrosis during pregnancy: a case report. ( Marisavljević, D; Marković, O; Terzić, T; Tukić, L; Zivković, R, 2015) |
| "A 20-year-old male with chronic myelogenous leukemia (CML) and severe bone marrow fibrosis underwent splenectomy, then ablative chemotherapy, followed by bone marrow transplantation from a histocompatible sister." | 1.27 | The reversal of myelofibrosis associated with chronic myelogenous leukemia after allogeneic bone marrow transplantation. ( Braylan, RC; Elfenbein, GJ; Jones, J; Oblon, DJ; Weiner, RS, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.69) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 5 (17.24) | 2.80 |
| Authors | Studies |
|---|---|
| Goulart, H | 1 |
| Mascarenhas, J | 1 |
| Tremblay, D | 1 |
| Mora, B | 1 |
| Passamonti, F | 1 |
| Loscocco, GG | 1 |
| Antonioli, E | 1 |
| Romano, I | 1 |
| Vergoni, F | 1 |
| Rotunno, G | 1 |
| Mannelli, F | 1 |
| Guglielmelli, P | 2 |
| Vannucchi, AM | 3 |
| Gangat, N | 1 |
| Al-Kali, A | 1 |
| Wolanskyj-Spinner, AP | 1 |
| Camoriano, J | 1 |
| Patnaik, MM | 1 |
| Pardanani, A | 1 |
| Hanson, CA | 1 |
| Tefferi, A | 5 |
| Choi, HS | 1 |
| Hong, J | 1 |
| Hwang, SM | 1 |
| Lee, JH | 1 |
| Ma, Y | 1 |
| Kim, SA | 1 |
| Lee, JY | 1 |
| Lee, JO | 1 |
| Bang, SM | 1 |
| Bohîlţea, RE | 1 |
| Cîrstoiu, MM | 1 |
| Ionescu, CA | 1 |
| Niculescu-Mizil, E | 1 |
| Vlădăreanu, AM | 1 |
| Voican, I | 1 |
| Dimitriu, M | 1 |
| Turcan, N | 1 |
| Barbui, T | 7 |
| Alvarez-Larrán, A | 1 |
| Cervantes, F | 2 |
| Besses, C | 1 |
| Pecci, A | 1 |
| Croci, G | 1 |
| Balduini, CL | 1 |
| Boveri, E | 1 |
| Yoshimoto, G | 1 |
| Miyamoto, T | 1 |
| Zivković, R | 1 |
| Marković, O | 1 |
| Marisavljević, D | 1 |
| Terzić, T | 1 |
| Tukić, L | 1 |
| Beer, PA | 1 |
| Green, AR | 3 |
| Vatutin, NT | 1 |
| Taradin, GG | 1 |
| Bakhteeva, TD | 1 |
| Kalinkina, NV | 1 |
| Skliannaia, EV | 1 |
| LEVRAT, M | 1 |
| MOREL, P | 1 |
| DEVIC, M | 1 |
| BRUN, F | 1 |
| Harrison, CN | 3 |
| Campbell, PJ | 2 |
| Buck, G | 2 |
| Wheatley, K | 2 |
| East, CL | 2 |
| Bareford, D | 2 |
| Wilkins, BS | 2 |
| van der Walt, JD | 1 |
| Reilly, JT | 1 |
| Grigg, AP | 1 |
| Revell, P | 1 |
| Woodcock, BE | 1 |
| Finazzi, G | 3 |
| Di Nisio, M | 1 |
| Di Gennaro, L | 1 |
| Borrelli, G | 1 |
| Landolfi, R | 2 |
| Leone, G | 1 |
| Marfisi, R | 1 |
| Porreca, E | 1 |
| Ruggeri, M | 1 |
| Rutjes, AW | 1 |
| Tognoni, G | 1 |
| Marchioli, R | 2 |
| Erber, WN | 1 |
| Paul, B | 1 |
| Viero, P | 1 |
| Cortelazzo, S | 1 |
| Bassan, R | 1 |
| Ireland, H | 1 |
| Lane, DA | 1 |
| Wolff, S | 1 |
| Foadi, M | 1 |
| Oblon, DJ | 1 |
| Elfenbein, GJ | 1 |
| Braylan, RC | 1 |
| Jones, J | 1 |
| Weiner, RS | 1 |
| Michiels, JJ | 1 |
| Kutti, J | 1 |
| Stark, P | 1 |
| Bazzan, M | 1 |
| Gugliotta, L | 1 |
| Griesshammer, M | 1 |
| van Genderen, PJ | 1 |
| Brière, J | 1 |
| Kiladjian, JJ | 1 |
| Berlin, NI | 1 |
| Pearson, TC | 1 |
| Green, AC | 1 |
| Fruchtmann, SM | 1 |
| Silver, RT | 1 |
| Hansmann, E | 1 |
| Wehmeier, A | 1 |
| Lengfelder, E | 1 |
| Kvasnicka, HM | 1 |
| Hasselbalch, H | 1 |
| Thiele, J | 1 |
| Silverstein, MN | 1 |
| Randi, ML | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Hansen, MS | 1 |
| Christensen, BE | 1 |
| Jønsson, V | 1 |
| Smelt, AH | 1 |
| van der Meer, FJ | 1 |
| Meinders, AE | 1 |
11 reviews available for aspirin and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quality of | 2022 |
SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
Topics: Aspirin; Humans; Hydroxyurea; Janus Kinase 2; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; | 2023 |
Primary myelofibrosis and pregnancy outcomes after low molecular-weight heparin administration: A case report and literature review.
Topics: Adult; Aspirin; Cesarean Section; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin, L | 2017 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, | 2014 |
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
[True polycythemia: current views of pathogenesis, diagnostics and treatment].
Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hema | 2012 |
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Topics: Aspirin; Bone Marrow; Bone Marrow Transplantation; Diagnosis, Differential; Follow-Up Studies; Granu | 1999 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Current trends in essential thrombocythaemia.
Topics: Acute Disease; Aspirin; Bone Marrow Examination; Clone Cells; Dosage Compensation, Genetic; Heparin, | 2002 |
2 trials available for aspirin and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F | 2005 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematolo | 2008 |
16 other studies available for aspirin and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethas | 2021 |
Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Diabetes, Gestational; Female; Fetal Death; Hemo | 2021 |
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu | 2021 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Cutaneous involvement by post-polycythemia vera myelofibrosis.
Topics: Aged; Aspirin; Biopsy; Cell Lineage; Disease Progression; Drug Therapy, Combination; Fibrosis; Hemat | 2014 |
Management of myelofibrosis during pregnancy: a case report.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinolytic | 2015 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
[Aleukemic megakaryocytic myelosis. Possible effect of massive ingestion of aspirin during ten years].
Topics: Aspirin; Eating; Leukemia; Primary Myelofibrosis | 1951 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia | 2005 |
The haematocrit and platelet target in polycythemia vera.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Female; Follow-Up Studi | 2007 |
Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases.
Topics: Adult; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Female; Humans; Leukemi | 1982 |
In vivo platelet release in myeloproliferative disorders.
Topics: Aged; Aspirin; beta-Thromboglobulin; Blood Platelets; Fibrinopeptide A; Fibrinopeptide B; Humans; Mi | 1982 |
The reversal of myelofibrosis associated with chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Topics: Adult; Allopurinol; Aspirin; Bone Marrow; Bone Marrow Transplantation; Busulfan; Drug Therapy, Combi | 1983 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
The effect of acetyl salicylic acid and dipyridamole on thromboembolic complications in splenectomized patients with myelofibrosis.
Topics: Aged; Aspirin; Blood Platelets; Cell Survival; Dipyridamole; Drug Therapy, Combination; Female; Huma | 1979 |
Erythromelalgia in a patient with myelofibrosis.
Topics: Aged; Aspirin; Erythromelalgia; Humans; Male; Platelet Count; Primary Myelofibrosis | 1988 |